Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

        Klaus F Rabe, Bartolome R Celli, Michael E Wechsler, et al

        Lancet Respiratory Medicine 2021 July 21

        High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap

        Pei Yee Tiew, Albert Yick Hou Lim, Holly R Keir, et al

        Chest 2021 August 5

        慢阻肺患者中的曲黴致敏問題國內學者也有關注，早在2014年孫永昌教授團隊就報告了慢阻肺中曲黴致敏和ABPA的發生情況及其對慢阻肺症狀及肺功能的影響。

        近期我們的臨床研究也證實有曲黴定植的慢阻肺患者急性加重風險上升。

        因此，慢阻肺患者下呼吸道曲黴定植/致敏/感染的出現、重疊和轉換值得臨床關注。

        Virus-induced Volatile Organic Compounds are Detectable in Exhaled Breath During Pulmonary Infection

        Faisal Kamal, Sacheen Kumar, Michael R Edwards, et al

        American Journal of Respiratory and Critical Care Medicine 2021 July 28

        Association Between Initiation of Pulmonary Rehabilitation and Rehospitalizations in Patients Hospitalized with COPD

        Mihaela S Stefan, Penelope S Pekow, Aruna Priya, et al

        American Journal of Respiratory and Critica lCare Medicine 2021 July 20

        從這項真實世界研究的大樣本數據分析看，因慢阻肺急性加重住院的患者，在出院後90天內早期啟動肺康複能夠降低一年內重新住院的風險。之前RCT已經有類似結果，但是實際上接受了PR處方的患者比例很低，隻有1.5%，因此需要確定有效的策略來增加PR的實施。

        Optimal Noninvasive Medicare Access Promotion: Patients with COPD Technical Expert Panel Report from the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society

        Nicholas S Hill, Gerard J Criner, Richard D Branson, et al

        Chest 2021 July 28